Paramdeep Bilkhu

Paramdeep Bilkhu

Auto-generated profile, based on publicly available information

Paramdeep Bilkhu

Ophthalmic Research Group, School of Life & Health Sciences, Aston University, Birmingham, B4 7ET, United Kingdom

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2014 in British Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
PBParamdeep Singh Bilkhu
Paramdeep Singh Bilkhu
SNShehzad A. Naroo
Shehzad A. Naroo
James S. WolffsohnJames S. Wolffsohn
James S. Wolffsohn
Background/aims To investigate the efficacy and safety of the MGDRx EyeBag (The Eyebag Company, Halifax, UK) eyelid warming device. Methods Twenty-five patients with confirmed meibomian gland dysfunction (MGD)-related evaporative dry eye were enrolled into a randomised, single masked, contralateral clinical trial. Test eyes received a heated device; control eyes a non-heated device for 5 min twice a day for 2 weeks. Efficacy (ocular symptomology, non-invasive break-up time, lipid layer thickness, osmolarity, meibomian gland dropout and function) and safety (visual acuity, corneal topography, conjunctival hyperaemia and staining) measurements were taken at baseline and follow-up. Subsequent patient device usage and ocular comfort was ascertained at 6 months. Results Differences between test and control eyes at baseline were not statistically significant for all measurements (p>0.05). After 2 weeks, statistically significant improvements occurred in all efficacy measurements in test eyes (p0.05). All patients maintained higher ocular comfort after 6 months (p<0.05), although the benefit was greater in those who continued usage 1–8 times a month (p<0.001). Conclusions The MGDRx EyeBag is a safe and effective device for the treatment of MGD-related evaporative dry eye. Subjective benefit lasts at least 6 months, aided by occasional retreatment. Trial registration number NCT01870180.

1 November 2015 in Optometry and Vision Science
Verified
Journal Article
Closed access
James S. WolffsohnJames S. Wolffsohn
James S. Wolffsohn
SMStephanie Mroczkowska
Stephanie Mroczkowska
OHOlivia A. Hunt
Olivia A. Hunt
PBParamdeep Bilkhu
Paramdeep Bilkhu
TDTom Drew
Tom Drew
ASAmy Sheppard
Amy Sheppard

1 January 2014 in Ophthalmology
Verified
Journal Article
Closed access
PBParamdeep S. Bilkhu
Paramdeep S. Bilkhu
James S. WolffsohnJames S. Wolffsohn
James S. Wolffsohn
SNShehzad A. Naroo
Shehzad A. Naroo
LRLouise Robertson
Louise Robertson
RKRoy Kennedy
Roy Kennedy

1 October 2015 in Contact Lens and Anterior Eye
Verified
Journal Article
Closed access
James S. WolffsohnJames S. Wolffsohn
James S. Wolffsohn
LHLee Hall
Lee Hall
SMStephanie Mroczkowska
Stephanie Mroczkowska
OHOlivia A. Hunt
Olivia A. Hunt
PBParamdeep Bilkhu
Paramdeep Bilkhu
ASAmy Sheppard
Amy Sheppard

1 February 2012 in Contact Lens and Anterior Eye
Verified
Journal Article
Closed access
PBParamdeep S. Bilkhu
Paramdeep S. Bilkhu
James S. WolffsohnJames S. Wolffsohn
James S. Wolffsohn
SNShehzad A. Naroo
Shehzad A. Naroo

1 February 2014 in Optometry and Vision Science
Verified
Journal Article
Closed access
PBParamdeep S. Bilkhu
Paramdeep S. Bilkhu
SNShehzad A. Naroo
Shehzad A. Naroo
James S. WolffsohnJames S. Wolffsohn
James S. Wolffsohn